Search results for "LDL"

showing 10 items of 664 documents

Periodontitis, blood lipids and lipoproteins

2014

Periodontitis, one of the most common chronic infections in adults, is characterized by the accumulation of dental plaque and infection by gram-negative pathogens bacteria, which further lead to the destruction of periodontal tissues. A relationship between chronic periodontitis and abnormalities in lipid and/or lipoprotein metabolism is not well understood yet. Periodontitis is associated with elevated pro-atherogenic plasma-lipids, including small dense LDL, while oxidized LDL may act as inflammatory stimulant in periodontitis. Periodontal pathogens may directly modify lipoprotein, including protective characteristics of HDL and contribute to development of metabolic syndrome, Type 2 diab…

Periodontitismedicine.medical_specialtybiologybusiness.industryEndocrinology Diabetes and MetabolismType 2 Diabetes MellitusBlood lipidsmedicine.diseasebiology.organism_classificationDental plaqueChronic periodontitiscardiovascular risk inflammation lipids lipoproteins periodontitis sdLDLchemistry.chemical_compoundEndocrinologychemistryLow-density lipoproteinInternal medicineImmunologymedicinelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessPorphyromonas gingivalisLipoproteinClinical Lipidology
researchProduct

Mildronate, a Regulator of Energy Metabolism, Reduces Atherosclerosis in apoE/LDLR<sup>–/–</sup> Mice

2009

<i>Background/Aims:</i> Mildronate, an inhibitor of <i>L</i>-carnitine biosynthesis and transport, is used in clinics as a modulator of cellular energy metabolism and is a cardioprotective drug. <i>L</i>-Carnitine is a pivotal molecule in fatty acid oxidation pathways and its regulation in vasculature might be a promising approach for antiatherosclerotic treatment. This study was performed to evaluate the effects of mildronate treatment on the progression of atherosclerosis and the content of <i>L</i>-carnitine in the vascular wall. <i>Methods:</i> ApoE/LDLR<sup>–/–</sup> mice received mildronate at doses of 30 and 100 …

PharmacologyApolipoprotein EBiochemistryCarnitine biosynthesisLDL receptorRegulatorEnergy metabolismGeneral MedicineMetabolismCellular energyBiologyCell biologyPharmacology
researchProduct

Up-regulation of cholesterol associated genes as novel resistance mechanism in glioblastoma cells in response to archazolid B

2014

Treatment of glioblastoma multiforme (GBM), the most common and aggressive lethal brain tumor, represents a great challenge. Despite decades of research, the survival prognosis of GBM patients is unfavorable and more effective therapeutics are sorely required. Archazolid B, a potent vacuolar H(+)-ATPase inhibitor influencing cellular pH values, is a promising new compound exerting cytotoxicity in the nanomolar range on wild-type U87MG glioblastoma cells and U87MG.∆EGFR cells transfected with a mutant epidermal growth factor receptor (EGFR) gene. Gene expression profiling using microarray technology showed that archazolid B caused drastic disturbances in cholesterol homeostasis. Cholesterol,…

PharmacologyCholesterolTransfectionBiologyToxicologyUp-RegulationSterol regulatory element-binding proteinGene expression profilingThiazoleschemistry.chemical_compoundCholesterolDownregulation and upregulationBiochemistrychemistryDrug Resistance NeoplasmCell Line TumorLDL receptorCancer researchbiology.proteinHumansV-ATPaselipids (amino acids peptides and proteins)MacrolidesEpidermal growth factor receptorGlioblastomaToxicology and Applied Pharmacology
researchProduct

Complement and Atherogenesis

1999

Abstract —Complement activation occurs in temporal correlation with the subendothelial deposition of LDL during early atherogenesis, and complement also plays a pathogenetic role in promoting lesion progression. Two lesion components have been identified that may be responsible for complement activation. First, enzymatic degradation of LDL generates a derivative that can spontaneously activate complement, and enzymatically degraded LDL (E-LDL) has been detected in the lesions. Second, C-reactive protein (CRP) colocalizes with complement C5b-9, as evidenced by immunohistological studies of early atherosclerotic lesions, so the possibility exists that this acute phase protein also fulfills a…

PhosphorylcholineNeuraminidaseComplement Membrane Attack ComplexCoronary Artery DiseaseBiologyPhospholipaseLesionPathogenesismedicineHumansElectrophoresis Gel Two-DimensionalTrypsinComplement Activationchemistry.chemical_classificationPhosphorylcholineC-reactive proteinAcute-phase proteinCholesterol LDLComplement C3Coronary VesselsMolecular biologyComplement systemC-Reactive ProteinEnzymeBiochemistrychemistryType C Phospholipasesbiology.proteinCalciummedicine.symptomCardiology and Cardiovascular MedicineProtein BindingArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

2017

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is…

PhytochemicalsMedicine (miscellaneous)030204 cardiovascular system & hematologyPharmacologyIntestinal absorption0302 clinical medicineRisk FactorsDrug Interactions030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and DieteticsEvidence-Based MedicineOrvostudományok3. Good healthObservational Studies as TopicLiverCardiovascular DiseasesFatty Acids Unsaturatedlipids (amino acids peptides and proteins)nutraceuticalposition papermedicine.medical_specialtyStatinCombination therapymedicine.drug_classKlinikai orvostudományok03 medical and health sciencesMeta-Analysis as TopiclipidmedicineHumansIntensive care medicineLife StyleTriglyceridesDyslipidemiasbusiness.industryProbioticsdyslipidemiaCholesterol HDLEvidence-based medicineCholesterol LDLmedicine.diseaseResidual riskIntestinal AbsorptionrecommendationsDietary SupplementsPosition paperObservational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal se…

2004

Background—Previous work indicated that enzymatically remodeled LDL (E-LDL) might activate complement in atherosclerotic lesions via a C-reactive protein (CRP)–dependent and CRP-independent pathway. We sought to substantiate this contention and determine whether both pathways drive the sequence to completion.Methods and Results—E-LDL was prepared by sequential treatment of LDL with a protease and cholesteryl esterase. Trypsin, proteinase K, cathepsin H, or plasmin was used with similar results. Functional tests were used to assess total complement hemolytic activity, and immunoassays were used to demonstrate C3 cleavage and to quantify C3a, C4a, C5a, and C5b-9. E-LDL preparations activated …

PlasminArteriosclerosisLipoproteinsCathepsin HPhysiology (medical)EndopeptidasesmedicineHumansComplement ActivationbiologyC-reactive proteinC4ADrug SynergismComplement System ProteinsSterol EsteraseProteinase KTrypsinImmunohistochemistryComplement systemLipoproteins LDLC-Reactive ProteinBiochemistrybiology.proteinCardiology and Cardiovascular MedicineLipoproteinmedicine.drugCirculation
researchProduct

Effectiveness of screening for known mutations in Sicilian patients with "probable" familial hypercholesterolemia.

2002

Background and Aim: More than 750 mutations in the low-density lipoprotein (LDL) receptor gene are currently known to cause familial hypercholesterolemia (FH), but the array of mutations varies considerably in different populations. The definition of essentially all the LDL receptor gene mutations in a population is therefore a prerequisite for the implementation of nation-wide genetic testing for FH. Methods and Results: In this study, a screening strategy based on PCR-enzymatic digestion and PCR-allele specific hybridisation procedures was used to evaluate the frequency distributions of 11 known mutations in a cohort of 214 unrelated subjects meeting the diagnostic criteria of "probable" …

Point mutationNutrition and DieteticsSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)ExonsPolymerase Chain ReactionFHCohort StudiesHyperlipoproteinemia Type IIGene FrequencyReceptors LDLMutationScreeningHumansGenetic TestingCardiology and Cardiovascular MedicineSicilyFood Science
researchProduct

Possible adverse impact of contaminants on Atlantic cod population dynamics in coastal ecosystems

2019

While many in-laboratory ecotoxicological studies have shown the adverse impact of pollutants to the fitness of an individual, direct evidence from the field on the population dynamics of wildlife animals has been lacking. Here, we provide empirical support for a negative effect of pollution on Atlantic cod ( Gadus morhua ) population dynamics in coastal waters of Norway by combining unique time series of juvenile cod abundance, body size, environmental concentration of toxic contaminants and a spatially structured population dynamics model. The study shows that mercury concentration might have decreased the reproductive potential of cod in the region despite the general decline in the env…

Pollutionmedia_common.quotation_subjectPopulation DynamicsPopulationWildlifeGeneral Biochemistry Genetics and Molecular BiologyAnimalsEcosystemeducationGeneral Environmental Sciencemedia_commonLocal adaptationPollutantVDP::Agriculture and fishery disciplines: 900::Fisheries science: 920education.field_of_studyEcologyGeneral Immunology and MicrobiologybiologyNorwayEcologyEnvironmental ExposureGeneral MedicineContaminationbiology.organism_classificationGadus morhuaEnvironmental scienceEstuariesGeneral Agricultural and Biological SciencesAtlantic codWater Pollutants Chemical
researchProduct

Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature.

2015

Objective: Familial hypobetalipoproteinemia (FHBL) is autosomal codominant disorder of lipoprotein metabolism characterized by low plasma levels of total cholesterol (TC), low-density lipoproteincholesterol (LDL-C) and apolipoprotein B (apoB) below the 5 th percentile of the distribution in the population. Patients with the clinical diagnosis of homozygous FHBL (Ho-FHBL) are extremely rare and few patients have been characterized at the molecular level. Here we report the medical history and the molecular characterization of one paediatric patient with clinical features of Ho-FHBL. Methods: A one month old infant with failure to thrive, severe hypocholesterolemia and acanthocytosis was clin…

ProbandAdultMaleAcanthocytosiSettore MED/09 - Medicina InternaApolipoprotein BPopulationDNA Mutational AnalysisBiologyHypobetalipoproteinemiasExonHumanseducationGeneGeneticseducation.field_of_studyHomozygoteIntronInfantCholesterol LDLAbetalipoproteinemiaIntronsAlternative SplicingHomozygous familial hypobetalipoproteinemiaCholesterolRNA splicingApolipoprotein B-100Mutationbiology.proteinlipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineApolipoprotein BMinigeneAtherosclerosis
researchProduct

Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene …

2001

The aims of this study were to examine the presence of mutations in the low-density lipoprotein receptor gene among subjects clinically diagnosed with familial hypercholesterolemia and to analyze whether the molecular diagnosis helps to predict the response to simvastatin treatment in our familial hypercholesterolemia population. Fifty-five probands and 128 related subjects with familial hypercholesterolemia were studied. Genetic diagnosis was carried out following a three-step protocol based on Southern blot and PCR-single strand conformational polymorphism analysis. A randomized clinical trial with simvastatin was conducted in 42 genetically diagnosed subjects with familial hypercholester…

ProbandAdultMalemedicine.medical_specialtySimvastatinEndocrinology Diabetes and MetabolismClinical BiochemistryPopulationFamilial hypercholesterolemiaBiologyBiochemistryHyperlipoproteinemia Type IIchemistry.chemical_compoundEndocrinologyHigh-density lipoproteinApolipoproteins EInternal medicinemedicineHumanseducationAgedApolipoproteins Beducation.field_of_studyCholesterolBiochemistry (medical)Cholesterol HDLnutritional and metabolic diseasesCholesterol LDLMiddle Agedmedicine.diseaseEndocrinologychemistryReceptors LDLSimvastatinLow-density lipoproteinMutationlipids (amino acids peptides and proteins)FemaleHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteinmedicine.drugThe Journal of clinical endocrinology and metabolism
researchProduct